Neal Shore describes his recent controversial paper on enzalutamide versus active surveillance in early prostate cancer. He has a keen interest in examining the over-diagnosis and over-treatment of patients with low-grade disease, particularly in patients and providers who become uncomfortable in maintaining fidelity to active surveillance.